SSA
ELEV

Schonfeld Strategic Advisors’s Elevation Oncology ELEV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-275,390
Closed -$71.4K – 2162
2025
Q1 		$71.4K Sell
275,390
-57,910
-17% -$33.1K ﹤0.01% 2053
2024
Q4 		$188K Sell
333,300
-210,000
-39% -$124K ﹤0.01% 1769
2024
Q3 		$326K Buy
543,300
+156,900
+41% +$233K ﹤0.01% 1619
2024
Q2 		$1.04M Buy
386,400
+209,969
+119% +$791K 0.01% 1190
2024
Q1 		$905K Buy
176,431
+162,331
+1,151% +$526K 0.01% 1268
2023
Q4 		$7.57K Sell
14,100
-3,100
-18% -$1.64K ﹤0.01% 1714
2023
Q3 		$11.4K Sell
17,200
-116,900
-87% -$118K ﹤0.01% 1576
2023
Q2 		$204K Buy
+134,100
New +$354K ﹤0.01% 1557
2021
Q4 		– Sell
-18,044
Closed -$141K – 2241
2021
Q3 		$141K Sell
18,044
-7,656
-30% -$82.8K ﹤0.01% 1862
2021
Q2 		$349K Buy
+25,700
New +$318K ﹤0.01% 1378

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Schonfeld Strategic Advisors's ELEV Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 275,390 shares — an estimated $71.4K sold.

Schonfeld Strategic Advisors first reported a position in ELEV in Q2 2021 and held it in 10 quarters. The position peaked at $1.04M in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 275,390 Elevation Oncology shares in Q2 2025, an estimated $71.4K.
  • Schonfeld Strategic Advisors first reported a position in Elevation Oncology in Q2 2021 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Elevation Oncology position peaked at $1.04M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.